Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,473.47
(
0.37%
)
US TECH 100
28,701.60
(
0.00%
)
Dow Jones
50,579.70
(
0.58%
)
Brent Oil
96.43
(
-4.69%
)
Bitcoin
76,603.46
(
-0.86%
)
News Focus
News Focus
Post# of 257628
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123010
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: upndown1313 post# 45544

Sunday, 04/22/2007 4:40:16 PM

Sunday, April 22, 2007 4:40:16 PM

Post# of 257628
>VPHM polymerase (HCV-796) is now in lead relative to other polymerases…<

HCV-796 has clearly gained ground relative to NM283 and R1626, but it is not yet in the lead. NVS and IDIX hope to have NM283 in phase-3 late this year or (more likely, IMO) early in 2008, pending a positive outcome in the drug-interaction study with ribavirin that is finishing up now. Even an early 2008 start would leave NM283 ahead of HCV-796.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today